Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Adaptive Single-Dose Trial to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Afabicin

NCT07758608 is registered in ClinicalTrials.gov with Debiopharm International SA as lead sponsor.

NCT NCT07758608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07758608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Adaptive Single-Dose Trial to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Afabicin
Lead sponsor
Debiopharm International SA
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
February 29, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment